Brazil Allergy Therapeutics Market Analysis

Brazil Allergy Therapeutics Market Executive Summary

Brazil Allergy Therapeutics Market was valued at $580 Mn in 2022 and is estimated to reach $1027 Mn in 2030, exhibiting a CAGR of 7.4% during the forecast period.

Allergens are harmless substances found in the environment that trigger an immunological response. Dust mites, pollen, mold, and frequent dietary triggers, including milk, eggs, soy, and almonds, can all cause these allergies. Severe allergic reactions, like anaphylaxis, can cause symptoms including a runny nose and stinging eyes, while lesser reactions might put a person in a coma and make breathing difficult. Immunotherapy, avoiding allergens, and utilizing prescription medications such as nasal corticosteroids and antihistamines are some methods for controlling allergies.

Allergies are rather common in Brazil, with between 30% and 40% of the population reportedly suffering from an allergy, with a noticeable rise. Of all the specific allergies, allergic rhinitis is the most common, affecting around 35%–40% of people and resulting in symptoms including a runny nose, itchy eyes, congestion, and sneezing that greatly impair their quality of life. Approximately 7%–10% of children and 3%–4% of adults suffer from food allergies, which are typically triggered by common allergens such as eggs, cow's milk, peanuts, almonds, and seafood. Severe responses from food allergies frequently require emergency medical intervention. An estimated 5%–10% of people have skin allergies, especially dermatitis, while 8% of people in Brazil have lung allergies, including asthma. Allergy responses to things like mold, dust mites, and pollen can cause asthma flare-ups.

Notable research institutes in Brazil, including the University of São Paulo and Fiocruz (Oswaldo Cruz Foundation), are actively advancing allergy treatment methodologies. In an innovative preventive approach, the University of São Paulo is now conducting a study to investigate the possibility of probiotics in managing and preventing food allergies in infants.

In order to treat respiratory allergies, such as allergic rhinitis, Fiocruz is leading the research on the creation of tablets known as allergen-specific immunotherapy (AIT). The intention is to change the face of respiratory allergy treatment by offering a more practical and easily available substitute for established injection-based therapies.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Allergies: The rising incidence of allergic conditions in the population, such as food allergies, skin allergies, and respiratory allergies, is the main factor driving the need for allergy therapy drugs.

Increased Awareness and Diagnosis: More access to healthcare, public health campaigns, and educational programs result in earlier and more accurate allergy diagnoses, which encourage people to seek treatment.

Changing Lifestyles and Environmental Factors: Increased exposure to environmental variables, urbanization, and lifestyle changes can all lead to a rise in the prevalence of allergies. Increased demand for allergy drugs may result from factors including dietary changes and air pollution.

Market Restraints

High Cost of Treatment: A considerable percentage of the population cannot afford many of the modern and successful allergy medicines, such as biologics and sublingual immunotherapy, due to their high cost. This may restrict patients access to the best possible care and market penetration.

Treatment Compliance and Adherence: Adherence to long-term regimens such as immunotherapy is crucial for the efficacy of allergy treatments. Ineffective patient adherence brought on by costs, difficulties, or adverse effects may decrease therapy efficacy and hamper market progress.

Regulatory Hurdles: If new pharmaceuticals and therapies are not licensed in a timely manner because of stringent regulatory requirements, patients might not receive revolutionary treatments. The market's growth could be hampered by the waiting period for licenses.

Healthcare Policies and Regulatory Landscape

Brazil has multiple regulatory bodies that oversee the country's healthcare policies and allergy treatment drug regulations. A vital role is played by the National Health Surveillance Agency (ANVISA), which is in charge of registering, observing, and controlling health items, including allergy drugs. The Brazilian Health Ministry sets general healthcare guidelines that affect allergy treatment accessibility and cost. Drug pricing is regulated by the Chamber of the Drug Market (CMED) to maintain equity and competition. New health technologies are evaluated by the National Committee for Health Technology Incorporation (CONITEC), which may have an effect on accessibility and reimbursement in the Unified Health System (SUS). In addition to the extensive regulatory framework already in place, professional associations such as the Brazilian Society of Allergy and Immunology (ASBAI) may help shape guidelines for allergy diagnosis and treatment. Keeping up with organizations like ANVISA and the Health Ministry is crucial to comprehending the state of Brazilian allergy treatment laws at the moment.

Competitive Landscape

Key Players

• GlaxoSmithKline (GSK)
• Sanofi
• Merck & Co.
• Novartis
• Bayer
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Chiesi Farmaceutici
• Eurofarma Laboratórios
• EMS